Effect of oral ursodeoxycholic acid on cholelithiasis following laparoscopic sleeve gastrectomy for morbid obesity

• Published in: Surgery for obesity and related diseases Vol. 15; no. 6; pp. 827 - 831
• Main Authors: Nabil, Tamer M., Khalil, Ahmed H., Gamal, Kareem
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.06.2019
• Subjects: Cholelithiasis; Morbid obesity; Sleeve gastrectomy; Ursodeoxycholic acid; Morbid obesity; Cholelithiasis; Sleeve gastrectomy; Ursodeoxycholic acid
• ISSN: 1550-7289; 1878-7533
• DOI: 10.1016/j.soard.2019.03.028

Laparoscopic sleeve gastrectomy (LSG) is a definitive solution for morbid obesity and its related co-morbidities. Cholelithiasis is a postoperative complication of LSG. The use of ursodeoxycholic acid (UDCA) after LSG is a proposed solution to reduce the incidence of cholelithiasis. To evaluate the effect of UDCA prophylaxis on cholelithiasis following LSG in morbidly obese patients. Two university hospitals in Egypt, Cairo, and Beni Suef Universities’ hospitals. This prospective study was conducted between July 2015 and March 2018 and included 200 patients scheduled for LSG. They were randomly divided into 2 groups. The UDCA group received a postoperative prophylaxis regimen for prevention of cholelithiasis in the form of 250 mg twice daily of UDCA for 6 months. The control group did not receive prophylactic treatment. Abdominal ultrasound was done at 3, 6, 9, and 12 months for all patients to detect cholelithiasis. The primary outcome measure was cholelithiasis. Only 6% of the UDCA group developed cholelithiasis compared with 40% in the control group (P < .001). Age, sex, initial body mass index, and excess weight loss at 6 months did not significantly affect cholelithiasis. UDCA treatment for 6 months after LSG is effective in the prevention of cholelithiasis.